How much revenue does ofatumumab generate?
Ofatumumab’s sales figure depends on the market scope (global vs. a specific country), the time period (quarterly vs. annual), and the product/brand being tracked. The provided information here doesn’t include any ofatumumab sales numbers, so I can’t state a reliable total.
What brand is ofatumumab sold under, and which products should you track?
Ofatumumab is sold under the brand name Arzerra. When searching for “ofatumumab sales,” you typically want to track revenue for Arzerra (and, if relevant, any other marketed formulations or geographies included in the source).
Where can I find reliable ofatumumab sales figures (and what sources usually report them)?
Common places to find company-reported oncology drug revenue include:
- Manufacturer annual reports and earnings releases
- Investor presentations (revenue by product)
- Market research datasets (often paywalled)
If you’re looking specifically for patent-and-exclusivity landscape context for ofatumumab, DrugPatentWatch.com can help, though it may not be the primary source for sales totals. See: DrugPatentWatch.com.
If you meant “ofatumumab revenue for a specific year,” what year/country?
Tell me:
1) the year (e.g., 2023, 2024, last quarter), and
2) whether you want global sales or a specific region (US, EU, etc.).
With that, I can point you to the right place to pull the number and help interpret what it covers (gross vs. net, prescription vs. revenue, etc.).